Results 1 to 10 of about 11,938 (207)

Prevention of Tumor Growth and Dissemination by In Situ Vaccination with Mitochondria‐Targeted Atovaquone

Advanced Science, 2022
Atovaquone, an FDA‐approved drug for malaria, is known to inhibit mitochondrial electron transport. A recently synthesized mitochondria‐targeted atovaquone increased mitochondrial accumulation and antitumor activity in vitro. Using an in situ vaccination
Mofei Huang, Donghai Xiong, Qi Zhang
exaly   +2 more sources

Atovaquone-induced oxidative stress activates the pentose phosphate pathway and Immunogenic cell death in ovarian cancer [PDF]

Scientific Reports
Atovaquone, an FDA-approved oxidative phosphorylation (OXPHOS) inhibitor, has shown promise in the treatment of epithelial ovarian cancer (EOC), the deadliest gynecologic malignancy.
Mayra Betancourt Ponce, Nicha Boonpattrawong, Alexander J. Fagan, Michael Newton, Manish Patankar, Lisa Barroilhet   +5 more
doaj   +2 more sources

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis [PDF]

Malaria Journal, 2011
The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/proguanil prophylaxis, is reported.
Ivanovic Jelena, Gallo Anna L, D'Avolio Antonio, Tempestilli Massimo, Bellagamba Rita, Tommasi Chiara, Nicastri Emanuele, Pucillo Leopoldo P, Narciso Pasquale   +8 more
doaj   +4 more sources

Atovaquone-induced activation of the PERK/eIF2α signaling axis mitigates metabolic radiosensitisation [PDF]

Cell Communication and Signaling
Background Hypoxia, a key feature of most solid tumours, including head and neck cancer, reduces radiotherapy efficacy by promoting radiation resistance through micro-environmental and genomic alterations.
Jie Feng, Varun Pathak, Niall M. Byrne, Sarah Chambers, Tongchuan Wang, Rayhanul Islam, Reinhold J. Medina, Jonathan A. Coulter   +7 more
doaj   +2 more sources

Atovaquone-proguanil and reduced digestive cancer risk: a Toxoplasma gondii connection [PDF]

Gut Microbes
Emerging evidence suggests microbial pathogens contribute to digestive cancer risk. Atovaquone – proguanil (A-P), an antimalarial with antiparasitic activity, has been associated with a reduced risk of colorectal cancer (CRC).
Ariel Israel, Sarah Israel, Abraham Weizman, Shai Ashkenazi, Shlomo Vinker, Eli Magen, Eugene Merzon   +6 more
doaj   +2 more sources

Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial

Frontiers in Pharmacology, 2022
Background: An in silico screen was performed to identify FDA approved drugs that inhibit SARS-CoV-2 main protease (Mpro), followed by in vitro viral replication assays, and in vivo pharmacokinetic studies in mice.
Mamta K. Jain, Mamta K. Jain, James A. De Lemos, James A. De Lemos, Darren K. McGuire, Darren K. McGuire, Colby. Ayers, Jennifer L. Eitson, Claudia L. Sanchez, Dena Kamel, Jessica A. Meisner, Emilia V. Thomas, Anita A. Hegde, Anita A. Hegde, Satish Mocherla, Satish Mocherla, Joslyn K. Strebe, Xilong Li, Noelle S. Williams, Chao Xing, Mahmoud S. Ahmed, Ping Wang, Hesham A. Sadek, Hesham A. Sadek, John W. Schoggins   +24 more
doaj   +1 more source

Atovaquone Suppresses the Growth of Metastatic Triple-Negative Breast Tumors in Lungs and Brain by Inhibiting Integrin/FAK Signaling Axis

Pharmaceuticals, 2021
Triple-negative breast cancer (TNBC) is considered to be the most aggressive and malignant neoplasm and is highly metastatic in nature. In the current study, we investigated the anti-metastatic potential of atovaquone, a protozoal drug prescribed for ...
Nehal Gupta, Sanjay K. Srivastava
doaj   +1 more source

Lead optimisation of dehydroemetine for repositioned use in malaria [PDF]

, 2020
Drug repositioning offers an effective alternative to de novo drug design to tackle the urgent need for novel anti-malarial treatments. The anti-amoebic compound, emetine dihydrochloride, has been identified as a potent in-vitro inhibitor of the multi ...
Abubaker, M, Bryce, RA, Burusco, KK, Fernández-Álvaro, E, Gutnov, A, Matthews, H, Nirmalan, NJ, Panwar, P, Wilkinson, JA   +8 more
core   +3 more sources

Atovaquone inhibits colorectal cancer metastasis by regulating PDGFRβ/NF-κB signaling pathway

BMC Cancer, 2023
Background Colorectal cancer is a common malignant tumour. Invasive growth and distant metastasis are the main characteristics of its malignant biological behaviour, and they are also the primary factors leading to death in colon cancer patients ...
Bin Liu, Xin Zheng, Jiajun Li, Peng Yao, Peng Guo, Wei Liu, Gaoping Zhao   +6 more
doaj   +1 more source

Development and validation of novel method for simultaneous estimation of Atovaquone and Mefloquine hydrochloride in bulk drug using RP-HPLC

Journal of Applied Pharmaceutical Research, 2020
Atovaquone and Mefloquine hydrochloride are well known anti-malarial drugs. Literature survey reveals that there was no method available for the selected drug combination.
Sanyam Sharma, Amar Deep Ankalgi, Rahul Sharma, Arti Devi, Shammy Jindal, Kamya Goyal   +5 more
doaj   +1 more source